BTK抑制剂奥布替尼对原发免疫性血小板减少症中抗体介导的血小板破坏的影响
本研究通过体外和体内实验探讨新型BTK抑制剂奥布替尼治疗原发免疫性血小板减少症(ITP)的可行性及机制。奥布替尼可抑制B细胞受体介导的B细胞活化、增殖、分化和促炎因子分泌,抑制巨噬细胞Fcγ受体介导的血小板吞噬和促炎因子产生;在活动性ITP小鼠模型中,奥布替尼通过抑制浆细胞分化、抗血小板抗体产生、促炎因子分泌及肝脾血小板吞噬,显著升高血小板计数。
要点
- 奥布替尼抑制B细胞受体介导的B细胞活化、增殖、分化和促炎因子分泌。
- 奥布替尼抑制巨噬细胞Fcγ受体介导的血小板吞噬和促炎因子产生。
- 在活动性ITP小鼠模型中,奥布替尼通过抑制浆细胞分化、抗血小板抗体产生、促炎因子分泌及肝脾血小板吞噬,显著升高血小板计数。
核心结论
- 奥布替尼可通过阻断抗体介导的血小板破坏,作为ITP的潜在治疗药物。
研究设计与样本
- 研究采用体外实验和体内实验探讨奥布替尼治疗ITP的可行性和机制。
主要发现
- 奥布替尼抑制B细胞受体介导的B细胞活化、增殖、分化和促炎因子分泌。
- 转录组测序显示,与健康对照相比,ITP患者的B细胞在炎症和分泌活性方面反应更亢进,奥布替尼可能通过下调核糖体和线粒体代谢改变B细胞状态。
- 奥布替尼抑制巨噬细胞Fcγ受体介导的血小板吞噬和促炎因子产生。
- 在活动性ITP小鼠模型中,奥布替尼治疗通过抑制浆细胞分化、抗血小板抗体产生、促炎因子分泌以及肝脾中的血小板吞噬,显著升高血小板计数。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary immune thrombocytopenia (ITP) is a haemorrhagic disorder with a complex pathogenesis, wherein autoreactive B-cell-mediated platelet destruction plays a crucial role. Bruton's tyrosine kinase (BTK) is widely expressed and essential for immune cells. Several BTK inhibitors have been used clinically to treat haematological malignancies, while few studies are focusing on the regulatory role of BTK in ITP. This study aims to explore the feasibility and underlying mechanisms of a novel BTK inhibitor orelabrutinib in the treatment of ITP through in vitro and in vivo experiments. Orelabrutinib could inhibit B-cell receptor-mediated B-cell activation, proliferation, differentiation and pro-inflammatory cytokine secretion. Transcriptome sequencing revealed that B cells of ITP patients were more hyper-responsive in inflammation and secretion activity compared to healthy controls, and orelabrutinib might alter B-cell status through downregulating ribosome and mitochondrial metabolism. Fcγ receptor-mediated platelet phagocytosis and pro-inflammatory cytokine production by macrophages were also suppressed by orelabrutinib. Furthermore, orelabrutinib treatment considerably elevated the platelet count in active ITP murine models by inhibiting plasma cell differentiation, anti-platelet antibody production, pro-inflammatory factor secretion and platelet phagocytosis in the livers and spleens. Taken together, orelabrutinib could serve as a potential therapeutic agent for ITP by blocking antibody-mediated platelet destruction.
引用
- Yu TS, Han SQ, Wang LJ, et al. Effects of orelabrutinib, a BTK inhibitor, on antibody-mediated platelet destruction in primary immune thrombocytopenia. Br J Haematol. 2025. PMID: 40069128. doi:10.1111/bjh.20045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。